XORTX Therapeutics Inc. (NASDAQ:XRTX – Get Free Report) saw a large decline in short interest during the month of October. As of October 30th, there was short interest totaling 122,511 shares, a decline of 48.3% from the October 15th total of 237,048 shares. Currently, 7.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 58,359 shares, the days-to-cover ratio is presently 2.1 days.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of XORTX Therapeutics in a research note on Monday, September 21st. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Read Our Latest Stock Report on XORTX Therapeutics
XORTX Therapeutics Price Performance
NASDAQ XRTX opened at $1.10 on Monday. The company has a 50-day simple moving average of $1.47 and a two-hundred day simple moving average of $2.03. XORTX Therapeutics has a 12-month low of $0.82 and a 12-month high of $3.60. The firm has a market cap of $2.00 million, a price-to-earnings ratio of -0.48 and a beta of 0.83.
XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The technology company reported ($0.21) EPS for the quarter.
XORTX Therapeutics Company Profile
XORTX Therapeutics Inc. (NASDAQ:XRTX) is a clinical-stage pharmaceutical company focused on developing therapies for conditions associated with dysregulated uric acid metabolism. The company’s research is centered on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of addressing kidney and other serious chronic diseases. XORTX’s development programs include XRx-008, an orally administered therapy being developed for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function.
See Also
- Five stocks we like better than XORTX Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
